Clinical Trials Search

Official Title: Integrated Cancer Repository for Cancer Research (iCaRe2) – Breast Cancer Collaborative Repository

Study Purpose: This registry/tissue bank focuses on the collection of detailed information and biological samples to help create a resource that will be helpful to cancer researchers to study risk factors for a number of different types of cancer and other diseases, which relate to cancer.

Status: Recruiting

Official Title: Center for International Blood and Marrow Transplant Research: Protocol for a Research Database for Hematopoietic Cell Transplantation and Cellular Therapies

Study Purpose: To gather health information from patients receiving stem cell transplants that can be used to find ways to make stem cell transplants work better. 

Status: Recruiting

Official Title: Post-Approval Study Protocol For Hybrid Convergent Epicardial RF Ablation And Endocardial Ablation For The Treatment Of Symptomatic Long-standing Persistent AF

Study Purpose: The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic longstanding persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.

Status: Recruiting

Official Title: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Study Purpose: To see if treating with olaparib compared to the usual approach which is observation,  is more successful in preventing pancreatic cancer from coming back 

Status: Recruiting

Official Title: Testing The Addition Of Chemotherapy Drug, Cisplatin, To Usual Radiation Therapy For Patients With Head And Neck Cancer

Study Purpose: To compare two treatment approaches currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone.  A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin.

Status: Recruiting

Official Title: Testing What Happens When An Immunotherapy Drug (Pembrolizumab) Is Added To Radiation Or Given By Itself Compared To The Usual Treatment Of Chemotherapy With Radiation After You Have Had Surgery For Your Recurrent Squamous Cell Carcinoma Of The Head And Neck

Study Purpose: To compare usual approach (chemotherapy plus radiation) to pembrolizumab alone and pembrolizumab in combination with radiation after having head and neck cancer surgically removed.

Status: Recruiting

Official Title: A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em

Study Purpose: To determine if cabozantinib or the combination of dabrafenib and trametinib works better to prolong the time until the tumor grows or spreads after initial treatment stops working.

Status: Recruiting

Official Title: Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR

Study Purpose: To evaluate the best objective response rate of AZD9291 (osimertinib) among patients with EGFR exon 20 insertions.

Status: Recruiting

Official Title: Randomized phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma

Study Purpose: To compare any good and bad effects of giving three drugs- ipilimumab, nivolumab, and sargramostim at the same time compared to just ipilimumab and nivolumab together.

Status: Recruiting

Official Title: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

Study Purpose: This study is being done to see how safe an investigational drug is and how well it will work to help people with Estrogen receptor positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), early breast cancer with an increased risk of recurrence. 

Status: Recruiting